Systemic Scleroderma Treatment Market: Introduction
An autoimmune disorder that affects the skin and internal organs is called systemic scleroderma. Autoimmune diseases occur when the immune system malfunctions and destroys the body's own tissues and organs.
In Greek, the term ‘scleroderma' means rough skin, and the disorder is distinguished by the deposition of scar tissue (fibrosis) on the skin and other organs. The disorder is sometimes called systemic sclerosis, as fibrosis may affect organs other than the skin. Excess development of a strong protein called collagen, which typically protects and maintains connective tissues in the body, is due to fibrosis. Systemic scleroderma can also affect the internal organs and can damage or cause the organs to malfunction. The esophagus, heart, lungs, and kidneys are the most frequently affected organs.
Request Brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=81482
Key Drivers, Restrains, and Opportunities of Global Systemic Scleroderma Treatment Market
Increase in prevalence of systemic scleroderma is boosting the demand for therapies used to treat the symptoms related to systemic scleroderma, thereby driving the treatment market. For instance, the documented prevalence of systemic scleroderma in Europe and North America was 7.2–33.9 and 13.5–44.3 per 100,000 people, respectively, while the annual occurrence figures was 0.6–2.3 and 1.4–5.6 per 100,000 people.
Pharmaceutical and biotechnology industries are focused on the development of new potential therapy for the treatment of systemic scleroderma, which is further driving the systemic scleroderma treatment market. For instance, in November 2020, Boehringer Ingelheim received approval for nintedanib from the European Commission, which is used in systemic sclerosis-associated interstitial lung disease in adults. Abbvie’s pipeline therapy ALPN-101 is used in systemic lupus erythematosus and has successfully completed Phase- 3 trial. Novartis has also successfully completed Phase 2 trial of Niliotinib for the treatment of systemic sclerosis, which in turn is estimated to boost the systemic scleroderma treatment market in the near future.
Request COVID Analysis on Systemic Scleroderma Treatment Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=81482
Exponential increase in the number of government interventions and services available to raise awareness about the condition and therapeutic alternatives is a major factor driving the development and demand for treatment of systemic scleroderma
Likewise, strong rise in understanding among the population regarding preventive healthcare is also estimated to fuel the demand during the forecast period. Increasing investment in R&D to improve care for systemic sclerosis is projected to further propel the market during the forecast period. The diagnosis and origin of the systemic sclerosis is still unclear, which makes it all the more difficult for doctors to choose medications for symptom relief, as each case of scleroderma is distinctive, which in turn is anticipated to hamper the market for treatment of systemic scleroderma.
Request customization on Systemic Scleroderma Treatment Market Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=81482
North America to Capture Major Share of Global Systemic Scleroderma Treatment Market
North America is expected to account for a major share of the global systemic scleroderma treatment market due to the high prevalence of systemic scleroderma in the region
As compared to the U.S., Europe holds a relatively minro share, primarily due to higher usage of generics and biosimilars for off-label systemic scleroderma therapy. In the U.K., demand for systemic scleroderma treatment is estimated to increase substantially during the forecast period owing to the introduction of biologics and small molecules for the treatment of systemic sclerosis and the indications for systemic sclerosis. In May 2016, the EMA approval of Uptravi for the treatment of Pulmonary Arterial Hypertension was announced by Actelion Pharmaceuticals Ltd., a subsidiary of Johnson and Johnson Services, Inc.
Generics and OTC medications are the basic treatment for scleroderma and its effects in developing areas. The chronic scleroderma care industry in Japan is witnessing price cuts and has easier access to new orphan therapies. Development in Latin America and MEA is anticipated to fuel access to bio similar and generic immunosuppressants.
Pre Book Systemic Scleroderma Treatment Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=81482<ype=S
Key Players Operating in Global Systemic Scleroderma Treatment Market
The global systemic scleroderma treatment market is highly consolidated due to the presence of key players. A large number of players hold a major share in their respective regions. Demand for products to treat diseases is increasing in emerging as well as developed markets. Several players in the market have high number of pipeline of therapy drugs for the treatment of systemic scleroderma, which is likely to drive the global systemic scleroderma treatment market in the near future.
Major players operating in the global systemic scleroderma treatment market are listed below:
Bristol-Myers Squibb Company
Boehringer Ingelheim International GmbH
Allergan
Actelion Pharmaceuticals Ltd
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc.
Biogen
Novartis AG
Teva Pharmaceutical Industries Ltd.
AstraZeneca
Celgene corporation
Ono pharmaceutical co. Ltd
Aspen Holdings
Corbus Pharmaceuticals
Pfizer Inc.
Eli Lilly and Company
Bayer AG
Argentis Pharmaceuticals, LLC.
Amgen Inc.
Sanofi
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”
Contact
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
